scPharma Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue Beat Views

 Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million

Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4

Inventory levels at the end of Q4 2023 consistent with the end of Q3 2023

Unaudited cash, cash equivalents and short-term investments of approximately $76 million as of December 31, 2023

https://www.globenewswire.com/news-release/2024/01/04/2804315/0/en/scPharmaceuticals-Announces-Preliminary-Unaudited-Q4-and-Full-Year-2023-Net-FUROSCIX-Revenue.html